scholarly journals Microbiota profile in new-onset pediatric Crohn’s disease: data from a non-Western population

Gut Pathogens ◽  
2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Mohammad I. El Mouzan ◽  
Harland S. Winter ◽  
Assad A. Assiri ◽  
Kirill S. Korolev ◽  
Ahmad A. Al Sarkhy ◽  
...  
2014 ◽  
Vol 15 (3) ◽  
pp. 382-392 ◽  
Author(s):  
Dirk Gevers ◽  
Subra Kugathasan ◽  
Lee A. Denson ◽  
Yoshiki Vázquez-Baeza ◽  
Will Van Treuren ◽  
...  

2018 ◽  
Vol 48 (11-12) ◽  
pp. 1242-1250 ◽  
Author(s):  
Tomer Ziv-Baran ◽  
Séamus Hussey ◽  
Malgorzata Sladek ◽  
Jorge Amil Dias ◽  
Javier Martin de Carpi ◽  
...  

2014 ◽  
Vol 147 (4) ◽  
pp. 932-934 ◽  
Author(s):  
Lindsay J. Hall ◽  
John Walshaw ◽  
Alastair J.M. Watson

2009 ◽  
Vol 136 (5) ◽  
pp. A-361
Author(s):  
Yamile Zabana ◽  
Esther Garcia-Planella ◽  
Manuel Van Domselaar ◽  
Míriam Mañosa ◽  
Jordi Gordillo ◽  
...  

2019 ◽  
Vol 7 ◽  
pp. 2050313X1989358
Author(s):  
Wasim Haidari ◽  
Sarah Al-Naqshabandi ◽  
Christine S Ahn ◽  
Richard S Bloomfeld ◽  
Steven R Feldman

IL-17 antagonism is among the most potent treatments for psoriasis. Generally safe, new onset and exacerbations of inflammatory bowel disease may occur in association with IL-17 therapy. We describe a patient with long-standing history of psoriasis and psoriatic arthritis in whom asymptomatic Crohn’s disease was identified during treatment with secukinumab. The patient underwent an elective colonoscopy for colorectal cancer screening which revealed inflammation and multiple ulcers in the terminal ileum suggestive of Crohn’s disease. While the patient did not have any gastrointestinal symptoms, he was diagnosed as having asymptomatic Crohn’s disease. Given the association of inflammatory bowel disease with secukinumab treatment, secukinumab was discontinued. Although in this patient, Crohn’s disease was identified during treatment with secukinumab, a direct causal relationship cannot be assumed. Medications that are effective for both psoriasis and inflammatory bowel disease may be a good choice in patients with psoriasis who have comorbid Crohn’s disease or develop inflammatory bowel disease during treatment with another biologic.


2013 ◽  
Vol 79 (7) ◽  
pp. 672-675 ◽  
Author(s):  
Cristen Litz ◽  
Paul D. Danielson ◽  
Michael Wilsey ◽  
Nicole M. Chandler

Crohn's disease (CD) is a chronic illness and radiographic evaluation is frequently used. Consequently, pediatric patients with CD who are diagnosed in childhood are at risk for high levels of radiation exposure during their lifetimes. We sought to evaluate the impact of magnetic resonance enterography (MRE) in management of pediatric patients with known or suspected Crohn's disease. A retrospective review of patients with known or suspected CD who underwent MRE for new onset of symptoms was conducted. All demographic data, clinical history, and results of all radiographic, endoscopic, and pathology studies were recorded. Twenty-eight patients with known or suspected CD underwent 31 MRE examinations. MRE showed active disease in 16 (52%), fistula or abscess in seven (22%), and no evidence of active disease in eight (26%). Sixty-five per cent of patients underwent MRE with no other radiation-based imaging used. Surgical intervention was deemed necessary after the MRE in 16 per cent. In all cases, surgical findings were consistent with MRE results. Nearly 60 per cent of patients with CD are managed based on the findings of MRE without additional radiographic evaluation. Based on the results of this retrospective study, we propose a clinical pathway for use of MRE in patients with known or suspected CD with new onset of symptoms.


2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Walid Mottawea ◽  
Cheng-Kang Chiang ◽  
Marcus Mühlbauer ◽  
Amanda E. Starr ◽  
James Butcher ◽  
...  

2009 ◽  
Vol 3 (1) ◽  
pp. S36
Author(s):  
Y. Zabana ◽  
E. Garcia-Planella ◽  
M. Van Domselaar ◽  
M. Mañosa ◽  
J. Gordillo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document